OpenLB
Open Library of Bioscience
Advanced Search
HemaSphere
Jun, 2024;8 (6): e89.

Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Andreas J M Ferreri, Gerald Illerhaus, Jeanette K Doorduijn, Dorothee P Auer, Jacoline E C Bromberg, Teresa Calimeri, Kate Cwynarski, Christopher P Fox, Khê Hoang-Xuan, Denis Malaise, Maurilio Ponzoni, Elisabeth Schorb, Carole Soussain, Lena Specht, Emanuele Zucca, Christian Buske, Mats Jerkeman, Martin Dreyling, EHA and ESMO Guidelines Committees
Author Information
  1. Andreas J M Ferreri: Lymphoma Unit, IRCCS San Raffaele Scientific Institute Milan Italy.
  2. Gerald Illerhaus: Department of Hematology Oncology, Stem-Cell Transplantation and Palliative Care, Klinikum Stuttgart Stuttgart Germany.
  3. Jeanette K Doorduijn: Department of Haematology, Erasmus MC Cancer Institute University Medical Center Rotterdam Rotterdam The Netherlands.
  4. Dorothee P Auer: Mental Health & Clinical Neurosciences Unit, School of Medicine University of Nottingham Nottingham UK.
  5. Jacoline E C Bromberg: Department of Neuro-Oncology, Erasmus MC Cancer Institute University Medical Center Rotterdam Rotterdam The Netherlands.
  6. Teresa Calimeri: Lymphoma Unit, IRCCS San Raffaele Scientific Institute Milan Italy.
  7. Kate Cwynarski: Department of Haematology University College Hospital London UK.
  8. Christopher P Fox: School of Medicine University of Nottingham Nottingham UK.
  9. Khê Hoang-Xuan: Department of Neurology 2 Mazarin APHP, Groupe Hospitalier Pitié-Salpêtrière, Sorbonne Université, ICM Paris France.
  10. Denis Malaise: Department of Ophthalmology Institut Curie Paris France.
  11. Maurilio Ponzoni: Lymphoma Unit, IRCCS San Raffaele Scientific Institute Milan Italy.
  12. Elisabeth Schorb: Department of Medicine I, Medical Center, Faculty of Medicine University of Freiburg Freiburg Germany.
  13. Carole Soussain: Clinical Hematology Unit, Institut Curie St Cloud France.
  14. Lena Specht: Department of Oncology, Rigshospitalet University of Copenhagen Copenhagen Denmark.
  15. Emanuele Zucca: Clinic of Medical Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale Bellinzona Switzerland.
  16. Christian Buske: Institute of Experimental Cancer Research, Comprehensive Cancer Center Ulm University Hospital of Ulm Ulm Germany.
  17. Mats Jerkeman: Department of Oncology Skåne University Hospital and Lund University Lund Sweden.
  18. Martin Dreyling: Department of Medicine III LMU University Hospital Munich Munich Germany.
PMID: 38836097 DOI: 10.1002/hem3.89

Abstract

This EHA-ESMO Clinical Practice Guideline provides key recommendations for managing primary DLBCL of the CNS.The guideline covers clinical, imaging and pathological diagnosis, staging and risk assessment, treatment and follow-up.Algorithms for first-line and salvage treatments are provided.The author group encompasses a multidisciplinary group of experts from different institutions and countries in Europe.Recommendations are based on available scientific data and the authors' collective expert opinion.

References

  1. J Clin Oncol. 2003 Jan 15;21(2):266-72 [PMID: 12525518]
  2. Br J Haematol. 2020 Jun;189(5):879-887 [PMID: 31997308]
  3. Neurology. 2002 May 28;58(10):1513-20 [PMID: 12034789]
  4. Neuro Oncol. 2012 Oct;14(10):1304-11 [PMID: 22952196]
  5. Blood. 2021 Oct 28;138(17):1519-1534 [PMID: 34036310]
  6. Leukemia. 2022 Jul;36(7):1720-1748 [PMID: 35732829]
  7. Leuk Lymphoma. 2019 Feb;60(2):515-518 [PMID: 30033836]
  8. Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):11-31 [PMID: 25863750]
  9. Blood. 2019 Sep 12;134(11):860-866 [PMID: 31320380]
  10. Lancet. 2009 Oct 31;374(9700):1512-20 [PMID: 19767089]
  11. Lancet Haematol. 2017 Nov;4(11):e510-e523 [PMID: 29054815]
  12. Bone Marrow Transplant. 2017 Aug;52(8):1113-1119 [PMID: 28436974]
  13. Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1429-39 [PMID: 16863926]
  14. J Clin Oncol. 2019 Apr 1;37(10):823-833 [PMID: 30785830]
  15. J Clin Oncol. 2006 Aug 20;24(24):3865-70 [PMID: 16864853]
  16. J Neurooncol. 2017 Jun;133(2):315-320 [PMID: 28432587]
  17. J Neurooncol. 2002 Jun;58(2):175-8 [PMID: 12164690]
  18. J Clin Oncol. 2013 Sep 1;31(25):3061-8 [PMID: 23569323]
  19. Br J Haematol. 2020 Aug;190(3):394-404 [PMID: 32232989]
  20. Neurology. 2004 Feb 24;62(4):548-55 [PMID: 14981169]
  21. Blood. 2015 Jul 2;126(1):76-9 [PMID: 25900979]
  22. Cancer Cell. 2017 Jun 12;31(6):833-843.e5 [PMID: 28552327]
  23. Blood. 2022 Sep 15;140(11):1229-1253 [PMID: 35653592]
  24. J Clin Oncol. 2005 Aug 1;23(22):5034-43 [PMID: 15955902]
  25. J Clin Oncol. 2005 Mar 1;23(7):1507-13 [PMID: 15735126]
  26. Br J Cancer. 2011 Oct 25;105(9):1414-8 [PMID: 21915121]
  27. Cancer. 2003 Jan 1;97(1):128-33 [PMID: 12491514]
  28. Cureus. 2016 Jul 18;8(7):e697 [PMID: 27570717]
  29. Cancer. 2000 Sep 15;89(6):1359-70 [PMID: 11002232]
  30. Ann Oncol. 2007 Nov;18(11):1851-5 [PMID: 17804469]
  31. Leukemia. 2017 Apr;31(4):846-852 [PMID: 27843136]
  32. Neurology. 2021 Sep 28;97(13):628-631 [PMID: 34580183]
  33. Am J Hematol. 2019 Apr;94(4):455-460 [PMID: 30663807]
  34. Neuro Oncol. 2018 Apr 9;20(5):687-694 [PMID: 29036697]
  35. Neuro Oncol. 2021 Jul 1;23(7):1056-1071 [PMID: 33560416]
  36. CNS Oncol. 2015;4(6):393-8 [PMID: 26507609]
  37. Am J Hematol. 2021 Jul 1;96(7):823-833 [PMID: 33864703]
  38. JAMA Oncol. 2021 Jul 01;7(7):993-1003 [PMID: 33956047]
  39. Front Oncol. 2019 Dec 04;9:1350 [PMID: 31867275]
  40. Blood. 2017 Jun 8;129(23):3071-3073 [PMID: 28356247]
  41. Clin Cancer Res. 2004 Sep 1;10(17):5643-6 [PMID: 15355887]
  42. Blood. 2022 Feb 3;139(5):792-796 [PMID: 34871363]
  43. Ann Oncol. 2015 Jul;26(7):1305-13 [PMID: 25701456]
  44. Lancet Oncol. 2019 Feb;20(2):216-228 [PMID: 30630772]
  45. J Clin Oncol. 2013 Nov 1;31(31):3971-9 [PMID: 24101038]
  46. Leukemia. 2022 Jul;36(7):1870-1878 [PMID: 35562406]
  47. J Clin Oncol. 2022 Nov 10;40(32):3692-3698 [PMID: 35834762]
  48. J Clin Oncol. 2003 Mar 15;21(6):1044-9 [PMID: 12637469]
  49. Neuro Oncol. 2021 Jan 30;23(1):122-133 [PMID: 32583848]
  50. Semin Oncol. 2003 Dec;30(6 Suppl 19):53-7 [PMID: 14765387]
  51. Ann Oncol. 2019 Apr 1;30(4):621-628 [PMID: 30698644]
  52. Lancet Haematol. 2021 Feb;8(2):e110-e121 [PMID: 33513372]
  53. Eur J Cancer. 2019 Aug;117:121-130 [PMID: 31279304]
  54. Br J Haematol. 2021 May;193(3):497-505 [PMID: 33620087]
  55. Haematologica. 2018 Jul;103(7):e296-e299 [PMID: 29472354]
  56. Hematol Oncol. 2019 Dec;37(5):548-557 [PMID: 31418878]
  57. J Clin Oncol. 2003 Jul 15;21(14):2726-31 [PMID: 12860951]
  58. J Clin Oncol. 2003 Nov 15;21(22):4151-6 [PMID: 14615443]
  59. Br J Haematol. 2019 Feb;184(3):348-363 [PMID: 30467845]
  60. Blood. 2022 Apr 14;139(15):2306-2315 [PMID: 35167655]
  61. Neurology. 2002 Nov 26;59(10):1557-62 [PMID: 12451197]
  62. J Clin Oncol. 2001 Feb 1;19(3):742-9 [PMID: 11157026]
  63. J Clin Oncol. 2006 Dec 20;24(36):5711-5 [PMID: 17116938]
  64. Neuro Oncol. 2023 Apr 6;25(4):687-698 [PMID: 36334050]
  65. J Neurooncol. 2006 Nov;80(2):159-65 [PMID: 16699873]
  66. Br J Haematol. 2004 Jul;126(2):202-8 [PMID: 15238140]
  67. Retina. 2019 Apr;39(4):679-684 [PMID: 30204732]
  68. Neuro Oncol. 2016 Sep;18(9):1297-303 [PMID: 26951382]
  69. Ann Oncol. 2010 Apr;21(4):842-850 [PMID: 19914958]
  70. Blood. 2005 Jan 15;105(2):496-502 [PMID: 15358629]
  71. J Clin Oncol. 2016 May 20;34(15):1757-63 [PMID: 26976424]
  72. Hematol Oncol. 2013 Sep;31(3):143-50 [PMID: 23161567]
  73. Haematologica. 2015 Apr;100(4):534-40 [PMID: 25480497]
  74. J Neurooncol. 2005 Sep;74(2):201-5 [PMID: 16193393]
  75. Blood Adv. 2020 Jul 28;4(14):3378-3381 [PMID: 32722778]
  76. Blood. 2019 Jul 18;134(3):252-262 [PMID: 31118164]
  77. Blood. 2015 Feb 26;125(9):1403-10 [PMID: 25568347]
  78. Fluids Barriers CNS. 2017 Jun 2;14(1):16 [PMID: 28577579]
  79. Lancet Haematol. 2016 May;3(5):e217-27 [PMID: 27132696]
  80. Neurology. 2008 Oct 21;71(17):1355-60 [PMID: 18936428]
  81. Lancet Oncol. 2010 Nov;11(11):1036-47 [PMID: 20970380]
  82. Blood Adv. 2020 Aug 11;4(15):3648-3658 [PMID: 32766857]
  83. Lancet Haematol. 2016 Aug;3(8):e388-97 [PMID: 27476790]
  84. Int J Cancer. 2008 Jul 1;123(1):187-94 [PMID: 18435450]
  85. Neurology. 2020 Mar 10;94(10):e1027-e1039 [PMID: 31907289]
  86. J Clin Oncol. 2003 Jun 15;21(12):2407-14 [PMID: 12805341]
  87. Ann Oncol. 2007 Jul;18(7):1145-51 [PMID: 17284616]
  88. Br J Haematol. 2019 Jul;186(1):180-183 [PMID: 30714128]
  89. Ann Oncol. 2009 Feb;20(2):319-25 [PMID: 18953065]
Journal Article
Article has an altmetric score of 20

Word Cloud

Created with Highcharts 10.0.0EHA-ESMOClinicalPracticeGuidelineThediagnosistreatmentfollow-upgroupprovideskeyrecommendationsmanagingprimaryDLBCLCNSguidelinecoversclinicalimagingpathologicalstagingriskassessmentAlgorithmsfirst-linesalvagetreatmentsprovidedauthorencompassesmultidisciplinaryexpertsdifferentinstitutionscountriesEuropeRecommendationsbasedavailablescientificdataauthors'collectiveexpertopinionPrimarycentralnervoussystemlymphomas:

Similar Articles

Cited By